---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-23-000038"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T16:26:24.655831+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Amneal Q3 net revenue $620M (+14% YoY); adjusted EBITDA $154M (+22%); guidance raised

## Summary
- Net revenue $620M (+14% YoY); GAAP net income $10M ($0.06 EPS) vs loss $0.02 in Q3 2022.
- Adjusted net income $60M; adjusted EBITDA $154M (+22%); adjusted EPS $0.19 vs $0.14.
- Generics revenue +12%, AvKARE +25%, Specialty +9%; all segments contributed to growth.
- FY2023 guidance affirmed after previously being raised; on track to launch 40+ generics; IPX203 on track for 2024.

## SEC filing metadata
- accession: 0001723128-23-000038
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312823000038/0001723128-23-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312823000038/amrx-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-23-000038
- JSON: https://secwatch.observer/filing/0001723128-23-000038.json
- Plain text: https://secwatch.observer/filing/0001723128-23-000038.txt

## Key facts
- Earnings Releases
  Amneal Pharmaceuticals, Inc. reported third quarter ended September 30, 2023 results: revenue $620 million, net income $10 million, EPS $0.06.
  - Period: third quarter ended September 30, 2023
  - Revenue: $620 million
  - Net income: $10 million
  - EPS: $0.06
  - Result: reported results
  source text: the information furnished pursuant to Item 2.02 of this report. --- EX-99.1 (EX-99.1) --- AMNEAL REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS ‒ Q3 2023 Net Revenue of $620 million; GAAP Net Income of $10 million; Diluted EPS of $0.06 ‒ ‒ Q3 2023 Adjusted Net Income (1) of $60 million; Adjusted EBITDA (1) of $154 million; Adjusted Diluted EPS (1) of $0.19 ‒
  evidence_url: https://www.sec.gov/Archives/edgar/data/1723128/000172312823000038/0001723128-23-000038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.